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Juan-han Yu1, Guang Li2, Jing Zhao2, Chong Han2, Xi-ming Yuan3 and En-hua Wang1*Abstract
Background: Histone deacetylase (HDAC) plays an important role in the deacetylation of histone, which can alter
gene expression patterns and affect cell behavior associated with malignant transformation. The aims of this study
were to investigate the relationships between HDAC1, HDAC2, clinicopathologic characteristics, patient prognosis
and apoptosis, to clarify the mechanism of upregulation of the Axis inhibitor Axin (an important regulator of the
Wnt pathway) by X-radiation and to elucidate the effect of siRNA on radiation therapy of non-small cell lung
cancer (NSCLC).
Methods: HDAC1 and HDAC2 expression levels were measured by immunohistochemistry and reverse transcription
PCR. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP-nick end labeling and
fluorescence activated cell sorting. BE1 cells expressing Axin were exposed to 2 Gy of X-radiation.
Results: Expression of HDAC1 and that of HDAC2 were correlated, and significantly higher in NSCLC tissues than in
normal lung tissues (P < 0.05). HDAC1 and HDAC2 expression was correlated with pTNM stage and negatively
correlated with differentiation of NSCLC and apoptotic index (P < 0.05). The prognosis of patients with low
expression of HDAC1 and HDAC2 was better than that of those with high expression. X-radiation and siRNA
inhibited HDAC1 and HDAC2 expression in NSCLC cells and Axin levels were significantly higher in BE1 cells.
Conclusions: X-radiation and siRNA inhibit expression of HDAC1 and HDAC2, weaken the inhibitory effect of HDAC
on Axin, upregulate Axin expression and induce apoptosis of lung cancer cells. Inhibition of HDAC1 and HDAC2 is a
means of enhancing the radiosensitivity of NSCLC.
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The Axis inhibitor (Axin) is the most important negative
regulatory factor in the Wnt signaling pathway, forming
the adenomatous polyposis coli (APC) multiprotein
complex with APC and glycogen synthase kinase-3β
(GSK-3β) to promote the degradation of β-catenin and
block Wnt signaling [1-3]. Our previous study found
that Axin can induce apoptosis and enhance the effect
of X-radiation in the treatment of non-small cell lung* Correspondence: wangeh@yahoo.cn
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reproduction in any medium, provided the orcancer (NSCLC). X-radiation can upregulate Axin ex-
pression in certain NSCLC tissues and induce apoptosis
of NSCLC cells by p53 and/or the JNK pathway [4].
Why Axin in other NSCLC tissues is not upregulated
by X-radiation, and the mechanism of upregulation, re-
main unclear.
Recent studies show that histone deacetylase (HDAC)
plays an important role in the deacetylation of histone,
which can alter gene expression patterns and affect cell
behavior associated with malignant transformation [5-8].
We suggest that HDAC might regulate the expression
of Axin in NSCLCs exposed to X-radiation. In this
study, we aimed investigate the relationships between
HDAC1, HDAC2, clinicopathologic characteristics, patient. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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upregulation by X-radiation and to elucidate the effect of
siRNA on radiation therapy of NSCLC.Methods
Patients
NSCLC tissues (95 cases) and normal lung tissues
(20 cases) were collected during surgical procedures per-
formed in the First Affiliated Hospital of China Medical
University. Patient survival time was measured as the
interval between the date of surgery and the date of
death due to recurrence/metastasis or the last follow-up
visit. There were 72 males and 23 females, with a me-
dian age of 58 years (33–76 years). According to the
TNM classification of the International Union Against
Cancer (2010), our samples comprised 40 stage I, 18
stage II, 35 stage III and two stage IV tumors. According
to pathologic type, there were 45 squamous carcinomas,
40 adenocarcinomas and 10 others. Twenty-nine tumors
were well differentiated, 24 moderately differentiated
and 42 poorly differentiated.
The study was conducted under the regulations of
the Institutional Review Board of China Medical Univer-
sity. Informed consent was obtained from all enrolled
patients before surgery.Cell culture, vectors, transfection and siRNAs
BE1 cells (a type of lung large cell carcinoma) were
kindly provided by Dr. Jie Zheng of the Medical School,
Peking University. pFLAG-CMV-5b-Axin was kindly
provided by Prof. Mark A. Perrella of Brigham &
Women’s Hospital, Boston, MA as described previously.
pFlag-CMV-5b was purchased from Sigma-Aldrich
(St. Louis, MO). Cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (Gibco-BRL, Gaithersburg, MD)
with 10% fetal calf serum. Untreated controls received
vehicle alone. Eighty percent confluent cells were trans-
fected with pFlag-CMV-5b-Axin using Lipofectamine-
2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Double stranded siRNAs
were transfected at a final concentration of 50 nM using
oligofectamine (Invitrogen, Karlsruhe, Germany) accord-
ing to the manufacturer’s protocol. siRNAs were pur-
chased from TaKaRa (Dalian, China). The sequences of
the siRNAs were: control, 50-C A G T C G C G T T T G
C G A C T G G dtdt-30; HDAC1, 50-G C A G A T G C
A G A G A T T C A A C dtdt-30; and HDAC2, 50-G C C
T C A T A G A A T C C G C A TG dtdt-30.X-radiation exposure of cell lines
Eighty percent confluent cells were irradiated (2 Gy)
with X-radiation (6 MV) and then cultured for 48 h.Immunohistochemical staining
Immunohistochemical staining was performed on 4 μm-
thick sequential tissue sections using a streptavidin–
peroxidase system (UltrasensitiveTM; MaiXin, Fuzhou,
China) according to the manufacturer’s instructions.
Briefly, sections were deparaffinized in xylems and
rehydrated with graded alcohols. Each specimen was
incubated with 3% hydrogen peroxide, followed by in-
cubation at 4°C overnight with the primary antibodies
anti-HDAC1 (1:100; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) and anti-HDAC2 (1:100; Santa
Cruz Biotechnology Inc.). Biotinylated IgG was used as
a secondary antibody (Cell Signaling Technologies,
Beverly, MA, USA). Slides were washed with phosphate
buffered saline and the antibody reaction was visualized
using a fresh substrate solution containing diaminoben-
zidine. Sections were counterstained with hematoxylin.
Immunostained slides were reviewed by two patholo-
gists independently. The proportions of cells exhibiting
HDAC1 or HDAC2 expression were categorized as fol-
lows: 0, less than 25%; 1, 26–50%; 2, 51–75%; or 3,
more than 75%. The staining intensity was categorized
by relative intensity as follows: 1, weak; 2, intermediate;
or 3, strong. The proportions and intensity scores were
then multiplied to obtain a total score. For the final
statistical analysis, scores less than 1 were considered
negative and scores of 2 or more were considered
positive.Reverse transcription (RT)-PCR
Total RNA was extracted from tissues or cells using
TRIzol reagent (Invitrogen) according to the manufac-
turer’s instructions. RT-PCR analysis was performed
using a TaKaRa RNA PCR Kit (AMV) Ver.3.0 (TaKaRa).
Primer sequences were as follows: HDAC1, sense 50-A G
C C A A G A G A G T C A A A A C A G A-30, anti-
sense 50-G G T C C A T T C A G G C C A A C T-30;
HDAC2, sense 50-A G C A T C A G G A T T C T G T
T A C G T T A A T G A-30, antisense 50-C A A C A C
C A T C A C C A T G A T G A A T A T C T-30; Axin,
sense 50-A C C G A A A G T A C A T T C T T G A T
A A C-30, antisense 50-T C C A T A C C T G A A C T C
T C T G C-30; and -actin, sense 50-A G A G C T A C G
A G C T G C C T G A C-30, antisense 50-A G T A C T
T G C G C T C A G G A G G A-30. PCR conditions
were: 94°C for 4 min; 94°C for 1 min, 53°C (HDAC1);
94°C for 4 min; 94°C for 1 min, 52°C (HDAC2); 94°C for
4 min; 94°C for 1 min, 52°C (Axin) and 55°C (β-actin)
for 30 s, 72°C for 30 s, 35 cycles; 72°C for 10 min. Pro-
ducts were resolved in 1% agarose gels and bands were
visualized by ethidium bromide staining. Densitometric
analysis of bands was performed using a BioImaging
System (UVP, CA, USA).
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Lysate (50 μg) from BE1 cells was resolved by 12% SDS-
PAGE and transferred to PVDF membranes (Sigma). Mem-
branes were blocked with 3% fetal bovine serum, incubated
with the primary antibodies anti-HDAC1 (1:1000, SantaFigure 1 Correlation between HDAC1 and HDAC2 in NSCLC tissue. Bo
(A, B), squamous cell carcinoma, T1N0M0. Case 2 (C, D), squamous cell carc
adenocarcinoma, T1N0M0. Immunohistochemical streptavidin–peroxidase mCruz Biotechnology Inc.), anti-HDAC2 (1:1000; Santa Cruz
Biotechnology Inc.), anti-Axin (1:400; Santa Cruz Biotech-
nology Inc.) and anti-β-actin (1:2000; A2066; Sigma) over-
night at 4°C. Samples were then incubated with
horseradish peroxidase-IgG secondary antibody and bandsth HDAC1 and HDAC2 expression is localized to the nucleus. Case 1
inoma, T2N0M0. Case 3 (E, F), adenocarcinoma, T3N1M0. Case 4 (G, H),
ethod, magnification × 200.
Table 1 Relationships among HDAC1 and HDAC2 in








– + – +
Gender
Male 38 34 0.254† 39 33
Female 9 14 0.532† 10 13 0.372†
Age (years)
< 58 26 21 28 19
≥ 58 21 27 0.532† 21 27 0.123†
Histologic type
SCC 22 23 25 20
AC 22 18 21 19
Others 3 7 0.366† 3 7 0.339†
Differentiation
Well/Moderate 33 20 33 20
Poor 14 28 0.005† 16 26 0.019†
pTNM stage*
I/II 34 24 35 23
III/IV 13 24 0.026† 14 23 0.032†
Lymphatic metastasis
No 27 21 28 20
Yes 20 27 0.182† 21 26 0.183†
SCC, squamous cell carcinoma; AC, adenocarcinoma.
*TNM staging system of the International Union Against Cancer (2010).
†Pearson’s χ2 test.
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Scientific Inc., Fremont, CA, USA). Band quantification
was performed using Quantity One (Bio-Rad, Hercules,
CA, USA). Experiments were performed in triplicate.
Apoptosis assay
Apoptosis in tissues was detected by terminal deoxynu-
cleotidyl transferase-mediated dUTP-nick end labeling
(TUNEL) using an In Situ Cell Death Detection Kit
(Roche Diagnostics GmbH, Mannheim, Germany) with
fluorescein, according to manufacturer’s protocol. Apop-
tosis of BE1 cells was assayed by annexin-V and propi-
dium iodide (PI) staining, detected by flow cytometry
(FAC-S Calibur; BD Bioscience, San Jose, CA, USA) and
analyzed using Modfit LT V3.0 software (Verity Software
House Inc., Topsham, ME, USA). Only annexin-V posi-
tive and PI negative cells were considered apoptotic. All
experiments were performed in triplicate.
Statistical analysis
All values were expressed as the mean ± SD. The statistics
package SPSS 11.0 (SPSS Inc., Chicago, IL) was used for
all analyses. The relationship between percentages of
HDAC1 and HDAC2 positive cells and apoptotic index
was analyzed by the bivariate correlation analytical
method (Spearman’s correlation analysis). Relationships of
HDAC1 and HDAC2 with clinical and pathologic factors
were analyzed using Pearson’s χ2 test. Variance analysis
(least-significant difference method) was used for the de-
tection of apoptosis on flow cytometry. Survival analysis
was performed on the relationship of HDAC1 and
HDAC2 with patient prognosis using the Kaplan–Meier
method (log-rank test). P < 0.05 was considered statisti-
cally significant.
Results
Correlation of HDAC1 and HDAC2 expression with
clinicopathologic factors and apoptosis in NSCLC
Normal lung tissues expressed higher levels of HDAC1
and HDAC2 than NSCLC tissues (positive rates of
HDAC1 and HDAC2 in normal lung tissues are both
85.0%, 17/20, positive rate of HDAC1 in NSCLC tissues is
50.5%, 48/95 and positive rate of HDAC2 in NSCLC tis-
sues is 48.4%, 46/95). Expression of HDAC1 appeared to
be correlated with expression of HDAC2 (P < 0.05). In
addition, HDAC1 and HDAC2 expression appeared to be
correlated with pTNM stage and negatively correlated
with degree of differentiation. The positive rates for well
and moderately differentiated cells (37.7%, 20/53 and
37.7%, 20/53, respectively) were significantly lower than
those for poorly differentiated cells (66.7%, 28/42 and
61.9%, 26/42, respectively) (P < 0.05). The positive rates
for stage I-II tumors (41.4%, 24/58 and 39.7%, 23/58, re-
spectively) were significantly lower than those for stageIII-IV (64.9%, 24/37 and 62.2%, 23/37, respectively)
(Figure 1, Table 1). No significant difference was found in
gender, age, histologic type or lymphatic metastasis.
TUNEL was used to detect apoptosis in 95 NSCLC tissue
samples. HDAC1 and HDAC2 expression were negatively
correlated with apoptotic index (rP = –0.315, P = 0.002
and rP = –0.322, P = 0.002, respectively) (Figure 2).
Correlation of HDAC1, HDAC2, apoptotic index and
patient prognosis in NSCLC
Survival time post-surgery ranged from 2 to 112 months
for the 95 cases of NSCLC; the average was 46.7 ±
3.6 months and the median was 36.0 ± 5.2 months. The
Kaplan–Meier method (log-rank test) was used to
analyze life span. The average survival time of the group
negative for HDAC1 expression was 60.6 ± 4.9 months,
with a median of 46.0 ± 6.9 months. The average survival
time of the group positive for HDAC1 expression was
32.4 ± 4.2 months, with a median of 22.0 ± 4.1 months.
The average survival time of the group negative for
HDAC2 expression was 52.5 ± 4.3 months, with a me-
dian of 45.0 ± 6.3 months. The average survival time of
the group positive for HDAC2 expression was 38.7 ±
Figure 2 Correlation between HDAC1 and HDAC2 and apoptosis in NSCLC tissues. Case 1 (A–C), positive for expression of HDAC1 and
HDAC2 but low apoptotic index. Case 2 (D–F), negative for expression of HDAC1 and HDAC2 and high apoptotic index. Immunohistochemical
streptavidin–peroxidase method and TUNEL, magnification × 200.
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istical analysis indicated that the prognosis of patients who
were negative for HDAC1 expression was significantly bet-
ter than that of those who were positive (P = 0.000). The
prognosis of patients who were negative for HDAC2
was significantly better than that of those who were
positive (P = 0.000) (Figure 3).
X-radiation downregulated expression of HDAC1 and
HDAC2 and upregulated Axin expression
To investigate the effect of X-radiation on the expression
of HDAC1, HDAC2 and Axin, BE1 cells were exposed to
X-radiation (2 Gy) and HDAC1, HDAC2 and Axin expres-
sion was measured 24 h later by RT-PCR and Western
blot. Expression of HDAC1 and HDAC2 was downregu-
lated, whereas that of Axin was upregulated (Figure 4).Figure 3 Relationship between HDAC1 and HDAC2 expression and su
survival from the time of surgery were measured in 95 NSCLC patients. The
significantly better than that of HDAC1 and HDAC2 positive patients (P = 0siRNAs downregulated expression of HDAC1 and HDAC2
and upregulated Axin expression
To investigate the effects of HDAC1 and HDAC2 on the
expression of Axin, we used a plasmid-based RNAi
method to knock down HDAC1 and HDAC2 expression.
Target sequences of human HDAC1 and HDAC2 were
designed and ligated into BE1 cells. The recombinant plas-
mids were screened by BamHI and HindIII digestion and
further verified by sequencing. The recombinant and its
control plasmid were transfected into cultured BE1 cells.
Twenty-four hours later, RNA expression of HDAC1 and
HDAC2 was determined by RT-PCR. The RNA levels of
HDAC1 and HDAC2 in BE1 cells transfected with
pAVU6-siHDAC1 or pAVU6-siHDAC2 were significantly
decreased compared with those of cells transfected with
an empty vector (EC109-U6). Protein levels of HDAC1,rvival time in NSCLC patients. HDAC1 and HDAC2 levels and
prognosis of patients negative for HDAC1 and HDAC2 was
.000).
Figure 4 HDAC1, HDAC2 and Axin expression in lung carcinoma cell line after siRNA and X-radiation exposure. (A) Western blot analysis
of lung carcinoma (BE1) cells after siRNA and X-radiation exposure. HDAC1 siRNA inhibited expression of HDAC1, HDAC2 siRNA inhibited
expression of HDAC2 and X-radiation inhibited expression of HDAC1 and HDAC2. Both HDAC siRNA and X-radiation upregulated protein
expression of Axin. (B) RT-PCR analysis of BE1 cells after siRNA and X-radiation exposure. HDAC1 siRNA inhibited expression of HDAC1, HDAC2
siRNA inhibited expression of HDAC2 and X-radiation inhibited expression of HDAC1 and HDAC2. Both HDAC siRNA and X-radiation upregulated
RNA expression of Axin. HBE, human bronchial epithelial cells.
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results similar to those for their RNA levels (Figure 4).
These results show that HDAC1and HDAC2 proteins
were efficiently knocked down by siRNA in BE1 cells,
whereas Axin protein was upregulated.HDAC1 and HDAC2 siRNAs and X-radiation enhanced
apoptosis of BE1 cells
Apoptosis was measured by flow cytometry. Only
annexin-V positive and PI negative cells were considered
apoptotic. It was found that BE1 cells expressing pFLAG-
cmv-5b-Axin exhibited increased apoptosis, to the level of
cells exposed to X-radiation. Treatment of the cells with
X-radiation further increased apoptosis (45.2 ± 4.1%). In
addition, treatment of the cells with HDAC1 or HDAC2
siRNA further increased apoptosis (61.4 ± 5.8% and 58.3 ±
3.4%, respectively). Thus, HDAC1and HDAC2 proteins
were efficiently knocked down by siRNAs in BE1 cells,
whereas Axin protein was upregulated and apoptosis
increased (Figure 5, Additional file 1).Figure 5 Effects of Axin, X-radiation and siRNA on apoptosis of
BE1 cells. BE1 cells were transiently transfected with Axin,
pretreated with vehicle and exposed or not exposed to X-radiation
and HDAC1 and HDAC2 siRNA (measured by flow cytometry). Both
X-radiation and HDAC1 and HDAC2 siRNA induced apoptosis of the
BE1 cells.Discussion
NSCLC accounts for about 80% of cases of lung cancer
[9]; however, the use and therapeutic effects of radiation
therapy are limited by the hyposensitivity of NSCLC to
radiation [10-13]. Our previous study found that Axin can
induce apoptosis and enhance the effects of X-radiation in
some cases of NSCLC, by upregulating Axin expres-
sion in certain parts of the NSCLC and inducing
apoptosis of NSCLC cells by p53 and/or the JNK path-
way [4]. It remains unclear why Axin is not upregulated
by X-radiation in other parts of NSCLCs. In these
regions, apoptosis is not upregulated, leading to failure
of radiotherapy. The mechanism by which X-radiation
upregulates Axin expression is also unclear.
The acetylation level of histone and non-histone pro-
teins in the nucleolus determines chromatin structure.
High levels of histone acetylation lead to an open chro-
matin configuration, providing access for specific tran-
scription factors and the general transcription machinery
[14,15]. HDACs deacetylate the ε-amino group of lysines
located at the N-terminal tail of histones, leading to a
tightly packed chromatin formation (heterochromatin)
and the suppression of gene expression [5,16,17]. Based
on the fact that in some NSCLCs Axin is not upregu-
lated by X-radiation [4], we hypothesized that HDAC1
and HDAC2 may be inhibitors of the upregulation of
Axin by X-radiation, and designed experiments to test
this. First, we measured protein expression of HDAC1
and HDAC2 in 95 NSCLC tissue samples by immuno-
histochemistry, and found that it was related to pTNM
stage and negatively correlated with the degree of differ-
entiation of NSCLC. These results indicate that HDAC1
and HDAC2 can play important roles in the pathologic
diagnosis and may be targets for knock-down in treat-
ment of NSCLC. Our previous study found that Axin
expression is positively correlated with apoptotic index,
and the prognosis of patients positive for Axin was sig-
nificantly better than that of Axin-negative patients.
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tive for HDAC1 and HDAC2 was significantly better
than that those who were positive, and that HDAC2 ex-
pression is negatively correlated with apoptotic index,
we designed siRNAs to knock down HDAC1 and
HDAC2 and measured Axin expression and apoptosis in
BE1 cells (a type of large cell lung carcinoma). We found
both RNA and protein expression of Axin to be upregu-
lated after HDAC1 and HDAC2 had been knocked down
by siRNA. These results suggest that Axin may be
related to HDAC1 and HDAC2 levels in NSCLC tissues
and cells, and that HDAC1 and HDAC2 can inhibit Axin
expression.
The hyposensitivity of NSCLC to X-radiation is a
major reason for failure of radiotherapy. Our previous
study showed that transfection of Axin into NSCLC
cells enhances their radiosensitivity [4]. X-radiation
increases Axin expression and induces apoptosis in
NSCLC tissues, though the mechanism remains un-
clear. In the present study, we found that both siRNA
and X-radiation can downregulate the expression of
HDAC1 and HDAC2. Combining our previous results
showing that X-radiation upregulates Axin expression
in some NSCLC tissues, we suggest that X-radiation
may inhibit HDAC1 and HDAC2 expression and
weaken the inhibitory effect of HDAC1 and HDAC2
on Axin, thereby upregulating Axin expression and in-
ducing apoptosis of cancer cells. Our finding that, in
some, NSCLCs, Axin was not upregulated by X-radiation
[4] is explained by our observation in the present study
that X-radiation did not completely inhibit HDAC1 and
HDAC2 in NSCLC tissues and cells. Flow cytometry
showed that siRNAs of HDAC1 and HDAC2 induced
apoptosis of BE1 cells and enhanced the apoptosis-
inducing effect of X-radiation.
Aberrant expression of HDACs has been found in various
types of cancer. For example, expression of HDAC1 mRNA
in human urinary bladder cancer specimens was signifi-
cantly higher than that in normal controls [18], and
increased mRNA expression of HDCA1 and HDAC2 was
detected in ovarian cancer tissues compared with normal
tissue samples [19]. Moreover, expression of HDAC1
mRNA was associated with clinicopathologic factors such
as tumor size and histologic grade in human breast cancer,
gastric cancer and glioblastoma [20-22]. These findings
suggest that HDACs might be targets for cancer therapy
[23-25].
Conclusions
We believe this study not only clarifies the issue of why
X-radiation upregulates Axin and induces apoptosis, and
explains why in some NSCLCs Axin is not upregulated
by X-radiation, but also elucidates the effect of siRNA
on radiation therapy of NSCLC.Additional file
Additional file 1: The apoptosis of the BE1 cells, measured by flow
cytometry.
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